Oxford Nanopore Technologies plc (OTCPK:ONTTF) Q4 2024 Results Conference Call March 4, 2025 4:30 AM ET Company Participants Gordon Sanghera - Chief Executive Officer Nick Keher - Chief Financial Officer Conference Call Participants Charles Weston - RBC James Gordon - JPMorgan Paul Cuddon - Deutsche Bank Sam England - Berenberg Giang Nguyen - Citi David Westenberg - Piper Sandler Miles Dixon - Peel Hunt Gordon Sanghera Good morning, and welcome to our 2024 full results. I'm Gordon Sanghera, Chief Executive of Oxford Nanopore, and I'm joined today by our CFO, Nick Keher.
Oxford Nanopore Technologies plc (OTCPK:ONTTF) Q2 2024 Earnings Conference Call September 3, 2024 5:00 AM ET Company Participants Gordon Sanghera - Chief Executive Officer Nicholas Keher - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citigroup Odysseas Manesiotis - Berenberg Capital Markets Charles Weston - RBC Capital Markets Zain Ebrahim - JPMorgan David Westenberg - Piper Sandler Paul Cuddon - Deutsche Numis James Orsborne - Stifel Gordon Sanghera Good morning, and welcome to our 2024 Half Year Interim Results Presentation. I'm Gordon Sanghera, Chief Executive of Oxford Nanopore, and I'm joined today by our CFO, Nick Keher.
2 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
10 Jun 2025 Date | | - Cons. EPS | - EPS |
4 Mar 2025 Date | | - Cons. EPS | - EPS |
3 Sep 2024 Date | | - Cons. EPS | - EPS |
10 Jun 2024 Date | | - Cons. EPS | - EPS |
2 Sep 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
10 Jun 2025 Date | | - Cons. EPS | - EPS |
4 Mar 2025 Date | | - Cons. EPS | - EPS |
3 Sep 2024 Date | | - Cons. EPS | - EPS |
10 Jun 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Gurdial Singh Sanghera Ph.D. CEO | OTC PINK Exchange | GB00BP6S8Z30 ISIN |
GB Country | 1,382 Employees | - Last Dividend | - Last Split | - IPO Date |
Oxford Nanopore Technologies plc stands at the forefront of the biotechnology industry, focusing on the pioneering research, development, manufacture, and commercialization of an innovative nanopore-based sequencing platform. This platform is capable of the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), catering to a global market that encompasses the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific regions. The company's operations are divided into Life Science Research Tools and Covid Testing segments, reflecting its diverse application range from scientific research to pandemic response efforts. Initially founded as Oxford NanoLabs Limited in 2005, the company rebranded to Oxford Nanopore Technologies plc in May 2008, with its headquarters located in Oxford, the United Kingdom. Its technological innovations serve a wide array of scientific and biomedical research fields, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. Through its advancements, Oxford Nanopore Technologies is contributing significantly to the global understanding and management of complex biological information.